A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
SIGA Technologies, Inc. is referred to throughout this report as “SIGA,” “the Company,” “we” or “us.” We are a commercial-stage pharmaceutical company. The Company sells its lead product, TPOXX® (“oral TPOXX®,” also known as "tecovirimat," "Tecovirimat SIGA," or "TEPOXX (tecovirimat)" in certain international markets), to the U.S. Government and international governments (including government affiliated entities). In certain international markets, the Company may sell TPOXX® through a distributor. Additionally, the Company sells the intravenous formulation of TPOXX® ("IV TPOXX®") to the U.S. Government. TPOXX® is an antiviral drug for the treatment of human smallpox disease caused by variola virus. On July 13, 2018, the United States Food & Drug Administration (“FDA”) approved the oral formulation of TPOXX® for the treatment of smallpox. The Company has been delivering oral TPOXX® to the U.S. Strategic National Stockpile ("Strategic Stockpile") since 2013.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 172M | 139M | 140M | 111M | 134M | 125M |
| Net Income | 74M | 59M | 68M | 34M | 69M | 56M |
| EPS | $1.03 | $0.82 | $0.95 | $0.46 | $0.91 | $0.71 |
| Free Cash Flow | 116M | 49M | 95M | 42M | 11M | 72M |
| ROIC | 30.0% | 26.4% | 32.9% | 19.3% | 39.7% | 49.9% |
| Gross Margin | 76.3% | 77.4% | 87.3% | 90.6% | 87.6% | 88.2% |
| Debt/Equity | 0.00 | 0.13 | 0.29 | 0.15 | 0.23 | 0.00 |
| Dividends/Share | $0.00 | $0.60 | $0.45 | $0.45 | $0.00 | - |
| Operating Income | 90M | 70M | 84M | 43M | 89M | 85M |
| Operating Margin | 52.4% | 50.4% | 59.8% | 38.5% | 66.7% | 67.6% |
| ROE | 36.6% | 28.7% | 34.6% | 19.9% | 39.8% | 43.4% |
| Shares Outstanding | 72M | 72M | 72M | 74M | 76M | 79M |
SIGA TECHNOLOGIES INC passes 5 of 9 quality checks, suggesting mixed fundamentals.
SIGA TECHNOLOGIES INC trades at 5.6x trailing earnings, compared to its 15-year median P/E of 6.3x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 6.8x vs a median of 7.2x. The company's 5-year average ROIC is 33.7% with a gross margin of 86.2%. Total shareholder yield (dividends) is 13.1%. At current prices, the estimated annualized return to fair value is +16.4%.
SIGA TECHNOLOGIES INC (SIGA) has a current P/E ratio of 5.6, compared to its historical median P/E of 6.3. The stock is currently considered Fair based on its historical valuation range.
SIGA TECHNOLOGIES INC (SIGA) has a 5-year average return on invested capital (ROIC) of 33.7%. This indicates strong capital allocation and a potential competitive advantage.
SIGA TECHNOLOGIES INC (SIGA) has a market capitalization of $328M. It is classified as a small-cap stock.
Yes, SIGA TECHNOLOGIES INC (SIGA) pays a dividend with a trailing twelve-month yield of 13.10%.
Based on historical P/E analysis, SIGA TECHNOLOGIES INC (SIGA) appears fair. The current P/E of 5.6 is 12% below its historical median of 6.3. The estimated fair value CAGR (P/E method) is -3.9%.
SIGA TECHNOLOGIES INC (SIGA) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
SIGA TECHNOLOGIES INC (SIGA) reported annual revenue of $139 million in its most recent fiscal year, based on SEC EDGAR filings.
SIGA TECHNOLOGIES INC (SIGA) has a net profit margin of 42.7%. This is a strong margin indicating high profitability.
SIGA TECHNOLOGIES INC (SIGA) generated $49 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
SIGA TECHNOLOGIES INC (SIGA) has a debt-to-equity ratio of 0.13. This indicates a conservatively financed balance sheet.
SIGA TECHNOLOGIES INC (SIGA) reported earnings per share (EPS) of $0.82 in its most recent fiscal year.
SIGA TECHNOLOGIES INC (SIGA) has a return on equity (ROE) of 28.7%. This indicates the company generates strong returns for shareholders.
SIGA TECHNOLOGIES INC (SIGA) has a 5-year average gross margin of 86.2%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 15 years of financial data for SIGA TECHNOLOGIES INC (SIGA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
SIGA TECHNOLOGIES INC (SIGA) has a book value per share of $2.99, based on its most recent annual SEC filing.